News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 21, 2025

CGM vs Traditional Monitoring

Author(s)Davida Kruger, MSN, APN-BC, BC-ADM , Jaime Murillo, MD, FACC, FASE , Ian Neeland, MD, FAHA, FACC

Experts discuss the clinical and practical factors that guide decision-making when recommending continuous glucose monitoring (CGM) vs traditional glucose monitoring for patients with type 2 diabetes.

Episodes in this series

1 KOL is featured in this series.

EP. 1 CGM: Redefining Type 2 Diabetes Management

EP. 2 Key Benefits of CGM Technology

EP. 2 Key Benefits of CGM Technology

EP. 3 CGM's Impact on Clinical Inertia

EP. 3 CGM's Impact on Clinical Inertia

EP. 4 CGM vs Traditional Monitoring

EP. 4 CGM vs Traditional Monitoring

EP. 5 Understanding CGM Metrics

EP. 5 Understanding CGM Metrics

EP. 6 Health Care System Integration

EP. 6 Health Care System Integration

EP. 7 CGM Coverage and Access

EP. 7 CGM Coverage and Access

EP. 8 Implementation Barriers

EP. 8 Implementation Barriers

EP. 9 Overcoming Access Challenges

EP. 9 Overcoming Access Challenges

EP. 10 Adoption Strategies

EP. 10 Adoption Strategies

EP. 11 The Metro Nashville Public Schools Initiative

EP. 11 The Metro Nashville Public Schools Initiative

EP. 12 Health Care Quality Impact

EP. 12 Health Care Quality Impact

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 14 Long-Term Outcomes Assessment

EP. 14 Long-Term Outcomes Assessment

EP. 15 Closing Perspectives

EP. 15 Closing Perspectives

Video content above is prompted by the following:

What clinical and practical factors guide your decision-making when recommending CGMs versus vs traditional glucose monitoring for patients with type 2 diabetes?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

Additional Emerging HER2-Targeted Therapies in NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

5 experts are featured in this series

Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP

February 3rd 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text